Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration

References

• Oike T, Suzuki Y, Sugawara K, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One. 2013;8(11):e78943. doi:10.1371/journal.pone.007894324265731
   PubMedGoogle Scholar
• Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58):9392–9400. doi:10.1038/sj.onc.120831115558011
   PubMed Web of Science ®Google Scholar
• Sminia P, Westerman BA. Blood-brain barrier crossing and breakthroughs in glioblastoma therapy. Br J Clin Pharmacol. 2016;81(6):1018–1020. doi:10.1111/bcp.1288126744058
   PubMedGoogle Scholar
• Anjum K, Shagufta BI, Abbas SQ, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother. 2017;92:681–689. doi:10.1016/j.biopha.2017.05.12528582760
   PubMedGoogle Scholar
• Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014;2014:869269. doi:10.1155/2014/86926925136634
   PubMed Web of Science ®Google Scholar
• Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467–488. doi:10.1007/978-1-60761-416-6_2119949937
   PubMedGoogle Scholar
• Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481–1493. doi:10.7150/thno.2125429556336
   PubMed Web of Science ®Google Scholar
• Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013;28(4):387–402. doi:10.3904/kjim.2013.28.4.38723864795
   PubMed Web of Science ®Google Scholar
• Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–754.23736003
   PubMed Web of Science ®Google Scholar
• Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 2008;15(10):711–715. doi:10.1038/gt.2008.3518356815
   PubMedGoogle Scholar
• Awad HA, Butler DL, Boivin GP, et al. Autologous mesenchymal stem cell-mediated repair of tendon. Tissue Eng. 1999;5(3):267–277. doi:10.1089/ten.1999.5.26710434073
   PubMedGoogle Scholar
• Shi S, Bartold PM, Miura M, Seo BM, Robey PG, Gronthos S. The efficacy of mesenchymal stem cells to regenerate and repair dental structures. Orthod Craniofac Res. 2005;8(3):191–199. doi:10.1111/j.1601-6343.2005.00331.x16022721
   PubMedGoogle Scholar
• Aleynik A, Gernavage KM, Mourad Y, et al. Stem cell delivery of therapies for brain disorders. Clin Transl Med. 2014;3:24. doi:10.1186/2001-1326-3-2425097727
   PubMedGoogle Scholar
• Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol. 2013;4:201. doi:10.3389/fimmu.2013.0020124027567
   PubMed Web of Science ®Google Scholar
• Matsushita T, Kibayashi T, Katayama T, et al. Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett. 2011;502(1):41–45. doi:10.1016/j.neulet.2011.07.02121798315
   PubMedGoogle Scholar
• Kallmeyer K, Pepper MS. Homing properties of mesenchymal stromal cells. Expert Opin Biol Ther. 2015;15(4):477–479.25539087
   PubMed Web of Science ®Google Scholar
• Khatab S, van Osch GJ, Kops N, et al. Mesenchymal stem cell secretome reduces pain and prevents cartilage damage in a murine osteoarthritis model. Eur Cell Mater. 2018;36:218–230. doi:10.22203/eCM.v036a1630398288
   PubMed Web of Science ®Google Scholar
• Secunda R, Vennila R, Mohanashankar AM, Rajasundari M, Jeswanth S, Surendran R. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study. Cytotechnology. 2015;67(5):793–807. doi:10.1007/s10616-014-9718-z24798808
   PubMed Web of Science ®Google Scholar
• Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 2006;(174):249–282.
   PubMedGoogle Scholar
• Su P, Tian Y, Yang C, et al. Mesenchymal stem cell migration during bone formation and bone diseases therapy. Int J Mol Sci. 2018;19:8. doi:10.3390/ijms19082343
   Web of Science ®Google Scholar
• Huang X, Zhang F, Wang H, et al. Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials. 2013;34(7):1772–1780. doi:10.1016/j.biomaterials.2012.11.03223228423
   PubMed Web of Science ®Google Scholar
• Li L, Guan Y, Liu H, et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano. 2011;5(9):7462–7470.21854047
   PubMed Web of Science ®Google Scholar
• Kalber TL, Ordidge KL, Southern P, et al. Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2016;11:1973–1983. doi:10.2147/IJN.S9425527274229
   PubMedGoogle Scholar
• Kim SW, Lee YK, Hong JH, et al. Mutual destruction of deep lung tumor tissues by nanodrug-conjugated stealth mesenchymal stem cells. Adv Sci (Weinh). 2018;5(5):1700860. doi:10.1002/advs.20170086029876212
   PubMedGoogle Scholar
• Li SD, Huang L. Non-viral is superior to viral gene delivery. J Control Release. 2007;123(3):181–183. doi:10.1016/j.jconrel.2007.09.00417935817
   PubMedGoogle Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.18654426
   PubMed Web of Science ®Google Scholar
• Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia. 2010;26(8):790–795. doi:10.3109/0265673100374574020653418
   PubMed Web of Science ®Google Scholar
• Khdair A, Chen D, Patil Y, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010;141(2):137–144. doi:10.1016/j.jconrel.2009.09.00419751777
   PubMed Web of Science ®Google Scholar
• Hainfeld JF, Lin L, Slatkin DN, Avraham Dilmanian F, Vadas TM, Smilowitz HM. Gold nanoparticle hyperthermia reduces radiotherapy dose. Nanomedicine. 2014;10(8):1609–1617. doi:10.1016/j.nano.2014.05.00624990355
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171. doi:10.1038/nrc156615738981
   PubMed Web of Science ®Google Scholar
• Li X, Wei Z, Lv H, et al. Iron oxide nanoparticles promote the migration of mesenchymal stem cells to injury sites. Int J Nanomedicine. 2019;14:573–589. doi:10.2147/IJN.S18492030666115
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang F, Wang Y, et al. Design considerations of iron-based nanoclusters for noninvasive tracking of mesenchymal stem cell homing. ACS Nano. 2014;8(5):4403–4414. doi:10.1021/nn406272624754735
   PubMedGoogle Scholar
• Wang X, Gao J, Ouyang X, Wang J, Sun X, Lv Y. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomedicine. 2018;13:5231–5248. doi:10.2147/IJN.S16714230237710
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133–150. doi:10.1038/nrneurol.2017.18829377008
   PubMed Web of Science ®Google Scholar
• Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–561. doi:10.1038/nature0952220944627
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200(6):629–638. doi:10.1046/j.1469-7580.2002.00064.x12162730
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25. doi:10.1016/j.nbd.2009.07.03019664713
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimers Dement. 2009;5(5):427–432. doi:10.1016/j.jalz.2009.06.00319751922
   PubMed Web of Science ®Google Scholar
• Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295–1312.15134482
   PubMed Web of Science ®Google Scholar
• Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci. 2007;25(1):231–238. doi:10.1111/j.1460-9568.2006.05275.x17241284
   PubMedGoogle Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12. doi:10.1016/j.drup.2015.02.00225791797
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2(1):45–59. doi:10.1093/neuonc/2.1.4511302254
   PubMed Web of Science ®Google Scholar
• Kang JH, Cho J, Ko YT. Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice. J Drug Target. 2019;27(1):103–110. doi:10.1080/1061186X.2018.149703729972326
   PubMed Web of Science ®Google Scholar
• Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82. doi:10.1016/j.pharmthera.2015.05.00525944528
   PubMed Web of Science ®Google Scholar
• Haar CP, Hebbar P, GCt W, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37(6):1192–1200. doi:10.1007/s11064-011-0701-122228201
   PubMed Web of Science ®Google Scholar
• Mukherjee B, McEllin B, Camacho CV, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009;69(10):4252–4259. doi:10.1158/0008-5472.CAN-08-485319435898
   PubMedGoogle Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra070812618669428
   PubMed Web of Science ®Google Scholar
• Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457–1472. doi:10.1093/annonc/mdx10628863449
   PubMed Web of Science ®Google Scholar
• Ku MC, Waiczies S, Niendorf T, Pohlmann A. Assessment of blood brain barrier leakage with gadolinium-enhanced MRI. Methods Mol Biol. 2018;1718:395–408. doi:10.1007/978-1-4939-7531-0_2329341021
   PubMedGoogle Scholar
• Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med. 2009;13(9A):2911–2925. doi:10.1111/j.1582-4934.2008.00434.x18657226
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584–1596. doi:10.1038/nm.340724309662
   PubMed Web of Science ®Google Scholar
• Schneider SW, Ludwig T, Tatenhorst L, et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol. 2004;107(3):272–276. doi:10.1007/s00401-003-0810-214730455
   PubMed Web of Science ®Google Scholar
• Dubois LG, Campanati L, Righy C, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418. doi:10.3389/fncel.2014.0005225565956
   PubMed Web of Science ®Google Scholar
• Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12):5171–5184.20044633
   PubMed Web of Science ®Google Scholar
• Kim SS, Harford JB, Pirollo KF, Chang EH. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: the promise of nanomedicine. Biochem Biophys Res Commun. 2015;468(3):485–489. doi:10.1016/j.bbrc.2015.06.13726116770
   PubMed Web of Science ®Google Scholar
• Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol. 2011;13(12):1339–1348. doi:10.1093/neuonc/nor13321914639
   PubMedGoogle Scholar
• Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia. 2011;13(12):1113–1121. doi:10.1593/neo.11133822241957
   PubMed Web of Science ®Google Scholar
• Oshiro S, Tsugu H, Komatsu F, et al. Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res. 2009;29(3):911–917.19414327
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. doi:10.1016/j.gendis.2016.04.00730258889
   PubMed Web of Science ®Google Scholar
• Sun YL, Patel A, Kumar P, Chen ZS. Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012;31(2):51–57. doi:10.5732/cjc.011.1046622257384
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Desai AS, Linette GP, June CH, O’Rourke DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429–1438.29509936
   PubMed Web of Science ®Google Scholar
• Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Genetically engineered T-Cells for malignant glioma: overcoming the barriers to effective immunotherapy. Front Immunol. 2018;9:3062. doi:10.3389/fimmu.2018.0306230740109
   PubMed Web of Science ®Google Scholar
• Egea V, von Baumgarten L, Schichor C, et al. TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ. 2011;18(5):853–863. doi:10.1038/cdd.2010.15421127499
   PubMed Web of Science ®Google Scholar
• Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016;7(1):125. doi:10.1186/s13287-016-0363-727581859
   PubMed Web of Science ®Google Scholar
• Lourenco S, Teixeira VH, Kalber T, Jose RJ, Floto RA, Janes SM. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol. 2015;194(7):3463–3474. doi:10.4049/jimmunol.140209725712213
   PubMed Web of Science ®Google Scholar
• Kalimuthu S, Zhu L, Oh JM, et al. Migration of mesenchymal stem cells to tumor xenograft models and in vitro drug delivery by doxorubicin. Int J Med Sci. 2018;15(10):1051–1061. doi:10.7150/ijms.2576030013447
   PubMed Web of Science ®Google Scholar
• Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. 2017;6(12):2115–2125. doi:10.1002/sctm.17-013829072369
   PubMed Web of Science ®Google Scholar
• Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012;64(8):739–748. doi:10.1016/j.addr.2011.06.01021740940
   PubMed Web of Science ®Google Scholar
• Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920–927. doi:10.1002/stem.64521557390
   PubMed Web of Science ®Google Scholar
• Ahn JO, Coh YR, Lee HW, Shin IS, Kang SK, Youn HY. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo. Anticancer Res. 2015;35(1):159–168.25550547
   PubMed Web of Science ®Google Scholar
• Hou L, Wang X, Zhou Y, et al. Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells. Tumour Biol. 2014;35(2):1239–1250. doi:10.1007/s13277-013-1165-524136741
   PubMedGoogle Scholar
• Clarke MR, Imhoff FM, Baird SK. Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and −2. Mol Carcinog. 2015;54(10):1214–1219.24819588
   PubMed Web of Science ®Google Scholar
• He N, Kong Y, Lei X, et al. MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. Cell Death Dis. 2018;9(10):1026. doi:10.1038/s41419-018-1111-y30297887
   PubMedGoogle Scholar
• Rhee KJ, Lee JI, Eom YW. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J Mol Sci. 2015;16(12):30015–30033. doi:10.3390/ijms16122621526694366
   PubMedGoogle Scholar
• Melzer C, Yang Y, Hass R. Interaction of MSC with tumor cells. Cell Commun Signal. 2016;14(1):20. doi:10.1186/s12964-016-0143-027608835
   PubMedGoogle Scholar
• Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16(1):31. doi:10.1186/s12943-017-0597-828148268
   PubMed Web of Science ®Google Scholar
• Marofi F, Vahedi G, Biglari A, Esmaeilzadeh A, Athari SS. Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer. Front Immunol. 2017;8:1770. doi:10.3389/fimmu.2017.0177029326689
   PubMedGoogle Scholar
• Gomari H, Moghadam MF, Soleimani M. Targeted cancer therapy using engineered exosome as a natura drug delivery vehicle. Oncotargets Ther. 2018;11:5753–5762. doi:10.2147/OTT.S173110
   PubMed Web of Science ®Google Scholar
• Lu JH, Peng BY, Chang CC, et al. Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine. Cancers. 2018;10:11. doi:10.3390/cancers10110400
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol. 2015;3:23. doi:10.3389/fcell.2015.0002325883937
   PubMedGoogle Scholar
• Gomez-Cuadrado L, Tracey N, Ma R, Qian B, Brunton VG. Mouse models of metastasis: progress and prospects. Dis Model Mech. 2017;10(9):1061–1074. doi:10.1242/dmm.03040328883015
   PubMed Web of Science ®Google Scholar
• Li GC, Zhang HW, Zhao QC, et al. Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor beta1. Oncol Lett. 2016;11(2):1089–1094. doi:10.3892/ol.2015.399726893697
   PubMedGoogle Scholar
• Melzer C, von der Ohe J, Hass R. Enhanced metastatic capacity of breast cancer cells after interaction and hybrid formation with mesenchymal stroma/stem cells (MSC). Cell Commun Signal. 2018;16(1):2. doi:10.1186/s12964-018-0215-429329589
   PubMedGoogle Scholar
• Namba H, Kawaji H, Yamasaki T. Use of genetically engineered stem cells for glioma therapy (Review). Oncol Lett. 2016;11(1):9–15.26870161
   PubMed Web of Science ®Google Scholar
• Wang S, Miao Z, Yang Q, Wang Y, Zhang J. The dynamic roles of mesenchymal stem cells in colon cancer. Can J Gastroenterol Hepatol. 2018;2018:7628763.30533404
   PubMed Web of Science ®Google Scholar
• De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 2016;8(3):73–87.27022438
   PubMed Web of Science ®Google Scholar
• Hocking AM. The role of chemokines in mesenchymal stem cell homing to wounds. Adv Wound Care (New Rochelle). 2015;4(11):623–630.26543676
   PubMed Web of Science ®Google Scholar
• Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One. 2012;7(4):e34608.22511954
   PubMed Web of Science ®Google Scholar
• Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation. 2012;126(3):314–324.22685115
   PubMed Web of Science ®Google Scholar
• Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206–216.19265660
   PubMed Web of Science ®Google Scholar
• Nitzsche F, Muller C, Lukomska B, Jolkkonen J, Deten A, Boltze J. Concise review:MSC adhesion cascade-insights into homing and transendothelial migration. Stem Cells. 2017;35(6):1446–1460.28316123
   PubMed Web of Science ®Google Scholar
• Zachar L, Bacenkova D, Rosocha J. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment. J Inflamm Res. 2016;9:231–240.28008279
   PubMedGoogle Scholar
• Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Translat. 2017;9:19–27.29662796
   PubMed Web of Science ®Google Scholar
• Roberts TK, Buckner CM, Berman JW. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. Front Biosci (Landmark Ed). 2010;15:478–536.20036831
   PubMed Web of Science ®Google Scholar
• Muller WA. The regulation of transendothelial migration: new knowledge and new questions. Cardiovasc Res. 2015;107(3):310–320.25987544
   PubMed Web of Science ®Google Scholar
• Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015;15(11):692–704.26471775
   PubMed Web of Science ®Google Scholar
• Teo GS, Ankrum JA, Martinelli R, et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells. 2012;30(11):2472–2486.22887987
   PubMed Web of Science ®Google Scholar
• Lu YR, Yuan Y, Wang XJ, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 2008;7(2):245–251.18059192
   PubMed Web of Science ®Google Scholar
• Dasari VR, Velpula KK, Kaur K, et al. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One. 2010;5(7):e11813.20676365
   PubMed Web of Science ®Google Scholar
• Yang C, Lei D, Ouyang W, et al. Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Biomed Res Int. 2014;2014:109389. doi:10.1155/2014/10938924971310
   PubMedGoogle Scholar
• Jiang X, Fitch S, Wang C, et al. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. Proc Natl Acad Sci U S A. 2016;113(48):13857–13862. doi:10.1073/pnas.161539611327849590
   PubMedGoogle Scholar
• Grisendi G, Spano C, D’Souza N, et al. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas. Stem Cells. 2015;33(3):859–869. doi:10.1002/stem.190325420617
   PubMed Web of Science ®Google Scholar
• Villars F, Guillotin B, Amedee T, et al. Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. Am J Physiol Cell Physiol. 2002;282(4):C775–C785. doi:10.1152/ajpcell.00310.200111880266
   PubMed Web of Science ®Google Scholar
• Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2009;113(18):4197–4205. doi:10.1182/blood-2008-09-17619819036701
   PubMed Web of Science ®Google Scholar
• Pacioni S, D’Alessandris QG, Giannetti S, et al. Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res Ther. 2017;8(1):53. doi:10.1186/s13287-017-0601-728279193
   PubMedGoogle Scholar
• Ho IA, Toh HC, Ng WH, et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells. 2013;31(1):146–155. doi:10.1002/stem.124723034897
   PubMedGoogle Scholar
• Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: drivers of the immunosuppressive tumor microenvironment in prostate cancer? Prostate. 2019;79(3):320–330. doi:10.1002/pros.2373830488530
   PubMed Web of Science ®Google Scholar
• Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614–2623. doi:10.1002/stem.18719650040
   PubMed Web of Science ®Google Scholar
• Li M, Zhang F, Chen K, et al. Nanoparticles and mesenchymal stem cells: a win-win alliance for anticancer drug delivery. RSC Adv. 2016;6(43):36910–36922. doi:10.1039/C6RA00398B
   Web of Science ®Google Scholar
• Wu J, Liu Y, Tang Y, et al. Synergistic chemo-photothermal therapy of breast cancer by mesenchymal stem cell-encapsulated yolk-shell GNR@HPMO-PTX nanospheres. ACS Appl Mater Interfaces. 2016;8(28):17927–17935. doi:10.1021/acsami.6b0567727356586
   PubMed Web of Science ®Google Scholar
• Encabo-Berzosa MM, Gimeno M, Lujan L, et al. Selective delivery of photothermal nanoparticles to tumors using mesenchymal stem cells as Trojan horses. RSC Adv. 2016;6(63):58723–58732. doi:10.1039/C6RA10058A
   Web of Science ®Google Scholar
• Kang S, Bhang SH, Hwang S, et al. Mesenchymal stem cells aggregate and deliver gold nanoparticles to tumors for photothermal therapy. ACS Nano. 2015;9(10):9678–9690. doi:10.1021/acsnano.5b0220726348606
   PubMedGoogle Scholar
• Roger M, Clavreul A, Venier-Julienne MC, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials. 2010;31(32):8393–8401. doi:10.1016/j.biomaterials.2010.07.04820688391
   PubMed Web of Science ®Google Scholar
• Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol. 2018;9:866. doi:10.3389/fimmu.2018.0086629755464
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662. doi:10.1038/nrd466326323545
   PubMed Web of Science ®Google Scholar
• Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017;19(4):445–457. doi:10.1016/j.jcyt.2017.02.00228233640
   PubMed Web of Science ®Google Scholar
• Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629. doi:10.1155/2012/80562922400027
   PubMedGoogle Scholar
• Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26(3):831–841. doi:10.1634/stemcells.2007-075818192232
   PubMed Web of Science ®Google Scholar
• Ahmed AU, Rolle CE, Tyler MA, et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 2010;18(10):1846–1856. doi:10.1038/mt.2010.13120588259
   PubMed Web of Science ®Google Scholar
• Xu G, Jiang XD, Xu Y, et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int. 2009;33(4):466–474. doi:10.1016/j.cellbi.2008.07.02318725309
   PubMed Web of Science ®Google Scholar
• Gunnarsson S, Bexell D, Svensson A, Siesjo P, Darabi A, Bengzon J. Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol. 2010;218(1–2):140–144. doi:10.1016/j.jneuroim.2009.10.01719914721
   PubMed Web of Science ®Google Scholar
• van Eekelen M, Sasportas LS, Kasmieh R, et al. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene. 2010;29(22):3185–3195. doi:10.1038/onc.2010.7520305695
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68(23):9614–9623. doi:10.1158/0008-5472.CAN-08-045119047138
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009;106(12):4822–4827. doi:10.1073/pnas.080664710619264968
   PubMed Web of Science ®Google Scholar
• Hong X, Miller C, Savant-Bhonsale S, Kalkanis SN. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery. 2009;64(6):1139–1146. discussion 1146-1137. doi:10.1227/01.NEU.0000345646.85472.EA19487894
   PubMed Web of Science ®Google Scholar
• Ryu CH, Park KY, Kim SM, et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem Biophys Res Commun. 2012;421(3):585–590. doi:10.1016/j.bbrc.2012.04.05022525671
   PubMed Web of Science ®Google Scholar
• Yao S, Li X, Liu J, Sun Y, Wang Z, Jiang Y. Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer. Drug Deliv. 2017;24(1):1372–1383. doi:10.1080/10717544.2017.137558028920712
   PubMed Web of Science ®Google Scholar
• Lee C, Hwang HS, Lee S, et al. Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater. 2017;29:13. doi:10.1002/adma.201700681
   Web of Science ®Google Scholar
• Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res. 2012;72(18):4807–4817. doi:10.1158/0008-5472.CAN-12-012322962275
   PubMedGoogle Scholar
• Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 2011;8(5):1559–1572. doi:10.1021/mp200161f21718006
   PubMedGoogle Scholar
• Egawa N, Lok J, Washida K, Arai K. Mechanisms of axonal damage and repair after central nervous system injury. Transl Stroke Res. 2017;8(1):14–21. doi:10.1007/s12975-016-0495-127566737
   PubMedGoogle Scholar
• Puentes F, Malaspina A, van Noort JM, Amor S. Non-neuronal cells in ALS: role of glial, immune cells and blood-CNS barriers. Brain Pathol. 2016;26(2):248–257. doi:10.1111/bpa.1235226780491
   PubMedGoogle Scholar
• Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci. 2009;10(3):235–241. doi:10.1038/nrn259119229242
   PubMed Web of Science ®Google Scholar
• Moeendarbary E, Weber IP, Sheridan GK, et al. The soft mechanical signature of glial scars in the central nervous system. Nat Commun. 2017;8:14787. doi:10.1038/ncomms1478728317912
   PubMedGoogle Scholar
• Geoffroy CG, Zheng B. Myelin-associated inhibitors in axonal growth after CNS injury. Curr Opin Neurobiol. 2014;27:31–38. doi:10.1016/j.conb.2014.02.01224608164
   PubMed Web of Science ®Google Scholar
• Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion. J Clin Invest. 2015;125(8):3226–3240. doi:10.1172/JCI8088326168219
   PubMedGoogle Scholar
• Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583–1591. doi:10.1038/bjc.2017.35629065107
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670–1690. doi:10.3390/cancers603167025125485
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–896. doi:10.1038/ni.193720856220
   PubMed Web of Science ®Google Scholar
• Qi L, Yu H, Zhang Y, et al. IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma. Oncotarget. 2016;7(44):71673–71685. doi:10.18632/oncotarget.1231727765933
   PubMedGoogle Scholar
• Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol. 2013;25(6):637–645. doi:10.1097/CCO.000000000000000624076584
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416. doi:10.1038/nrclinonc.2016.21728117416
   PubMed Web of Science ®Google Scholar
• Vasandan AB, Jahnavi S, Shashank C, Prasad P, Kumar A, Prasanna SJ. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism. Sci Rep. 2016;6:38308. doi:10.1038/srep3830827910911
   PubMed Web of Science ®Google Scholar
• Saqib U, Sarkar S, Suk K, Mohammad O, Baig MS, Savai R. Phytochemicals as modulators of M1-M2 macrophages in inflammation. Oncotarget. 2018;9(25):17937–17950. doi:10.18632/oncotarget.2478829707159
   PubMedGoogle Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–795. doi:10.1172/JCI5964322378047
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737. doi:10.1038/nri307321997792
   PubMed Web of Science ®Google Scholar
• Kyurkchiev D, Bochev I, Ivanova-Todorova E, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells. 2014;6(5):552–570. doi:10.4252/wjsc.v6.i5.55225426252
   PubMedGoogle Scholar
• Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392–402. doi:10.1016/j.stem.2013.09.00624094322
   PubMed Web of Science ®Google Scholar
• Zhang QZ, Su WR, Shi SH, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28(10):1856–1868. doi:10.1002/stem.50320734355
   PubMed Web of Science ®Google Scholar
• Li J, Tan J, Martino MM, Lui KO. Regulatory T-Cells: potential regulator of tissue repair and regeneration. Front Immunol. 2018;9:585. doi:10.3389/fimmu.2018.0058529662491
   PubMed Web of Science ®Google Scholar
• Kandasamy M, Lehner B, Kraus S, et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J Cell Mol Med. 2014;18(7):1444–1459. doi:10.1111/jcmm.1229824779367
   PubMedGoogle Scholar
• Azizzadeh F, Mahmoodi J, Sadigh-Eteghad S, Farajdokht F, Mohaddes G. Ghrelin exerts analgesic effects through modulation of IL-10 and TGF-beta levels in a rat model of inflammatory pain. Iran Biomed J. 2017;21(2):114–119. doi:10.18869/acadpub.ibj.21.2.11427703278
   PubMedGoogle Scholar
• Dombrowski Y, O’Hagan T, Dittmer M, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20(5):674–680. doi:10.1038/nn.452828288125
   PubMed Web of Science ®Google Scholar
• Vidal PM, Lemmens E, Dooley D, Hendrix S. The role of “anti-inflammatory” cytokines in axon regeneration. Cytokine Growth Factor Rev. 2013;24(1):1–12. doi:10.1016/j.cytogfr.2012.08.00822985997
   PubMed Web of Science ®Google Scholar
• Cooney DS, Wimmers EG, Ibrahim Z, et al. Mesenchymal stem cells enhance nerve regeneration in a rat sciatic nerve repair and hindlimb transplant model. Sci Rep. 2016;6:31306. doi:10.1038/srep3130627510321
   PubMed Web of Science ®Google Scholar
• Marconi S, Castiglione G, Turano E, et al. Human adipose-derived mesenchymal stem cells systemically injected promote peripheral nerve regeneration in the mouse model of sciatic crush. Tissue Eng Part A. 2012;18(11–12):1264–1272. doi:10.1089/ten.TEA.2011.049122332955
   PubMedGoogle Scholar
• Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61(4):364–370. doi:10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C10931522
   PubMed Web of Science ®Google Scholar
• Deng WW, Obrocka M, Fischer I, Prockop DJ. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem Bioph Res Co. 2001;282(1):148–152. doi:10.1006/bbrc.2001.4570
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol. 2000;164(2):247–256. doi:10.1006/exnr.2000.738910915564
   PubMed Web of Science ®Google Scholar
• Hofstetter CP, Schwarz EJ, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A. 2002;99(4):2199–2204. doi:10.1073/pnas.04267829911854516
   PubMedGoogle Scholar
• Wislet-Gendebien S, Wautier F, Leprince P, Rogister B. Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res Bull. 2005;68(1–2):95–102. doi:10.1016/j.brainresbull.2005.08.01616325009
   PubMedGoogle Scholar
• Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109(10):1292–1298. doi:10.1161/01.CIR.0000121425.42966.F114993122
   PubMed Web of Science ®Google Scholar
• Wei X, Du Z, Zhao L, et al. IFATS collection: the conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells. 2009;27(2):478–488. doi:10.1634/stemcells.2008-033319023032
   PubMed Web of Science ®Google Scholar
• Tan B, Luan Z, Wei X, et al. AMP-activated kinase mediates adipose stem cell-stimulated neuritogenesis of PC12 cells. Neuroscience. 2011;181:40–47. doi:10.1016/j.neuroscience.2011.02.03821352901
   PubMedGoogle Scholar
• Olson SD, Pollock K, Kambal A, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington’s disease. Mol Neurobiol. 2012;45(1):87–98. doi:10.1007/s12035-011-8219-822161544
   PubMed Web of Science ®Google Scholar
• Pollock K, Dahlenburg H, Nelson H, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in huntington’s disease mouse models. Mol Ther. 2016;24(5):965–977. doi:10.1038/mt.2016.1226765769
   PubMedGoogle Scholar
• Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010;5(6):933–946. doi:10.2217/rme.10.7221082892
   PubMedGoogle Scholar
• Horner PJ, Gage FH. Regenerating the damaged central nervous system. Nature. 2000;407(6807):963–970. doi:10.1038/3503955911069169
   PubMed Web of Science ®Google Scholar
• Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004;5(2):146–156. doi:10.1038/nrn132614735117
   PubMed Web of Science ®Google Scholar
• Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/beta-catenin pathway. ACS Nano. 2014;8(1):76–103. doi:10.1021/nn405077y24467380
   PubMed Web of Science ®Google Scholar
• Schmidt N, Schulze J, Warwas DP, et al. Long-term delivery of brain-derived neurotrophic factor (BDNF) from nanoporous silica nanoparticles improves the survival of spiral ganglion neurons in vitro. PLoS One. 2018;13(3):e0194778. doi:10.1371/journal.pone.019477829584754
   PubMedGoogle Scholar
• Stachowiak EK, Roy I, Lee YW, et al. Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain. Integr Biol (Camb). 2009;1(5–6):394–403. doi:10.1039/b902617g20023746
   PubMedGoogle Scholar
• Bakker RC, van Es RJJ, Rosenberg A, et al. Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: preliminary results of first use. Nucl Med Commun. 2018;39(3):213–221. doi:10.1097/MNM.000000000000079229309367
   PubMedGoogle Scholar
• Tran C, Damaser MS. Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev. 2015;82–83:1–11. doi:10.1016/j.addr.2014.10.007
   PubMed Web of Science ®Google Scholar
• Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008;77(1):134–142. doi:10.1093/cvr/cvm02518006467
   PubMedGoogle Scholar
• Xu Y, Shi TP, Xu AX, Zhang L. 3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney. J Cell Mol Med. 2016;20(7):1203–1213. doi:10.1111/jcmm.1265126914637
   PubMed Web of Science ®Google Scholar
• Cunningham CJ, Redondo-Castro E, Allan SM. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J Cereb Blood Flow Metab. 2018;38(8):1276–1292.29768965
   PubMed Web of Science ®Google Scholar
• Cantinieaux D, Quertainmont R, Blacher S, et al. Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: an original strategy to avoid cell transplantation. PLoS One. 2013;8(8):e69515. doi:10.1371/journal.pone.006951524013448
   PubMed Web of Science ®Google Scholar
• Drago D, Cossetti C, Iraci N, et al. The stem cell secretome and its role in brain repair. Biochimie. 2013;95(12):2271–2285. doi:10.1016/j.biochi.2013.06.02023827856
   PubMed Web of Science ®Google Scholar
• Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:9. doi:10.3390/ijms18091852
   Web of Science ®Google Scholar